Lantheus - LNTH Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings or view top-rated stocks.

5 analysts have issued 1 year price objectives for Lantheus' stock. Their LNTH share price forecasts range from $91.00 to $120.00. On average, they anticipate the company's share price to reach $102.80 in the next year. This suggests a possible upside of 75.3% from the stock's current price.
View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts.

Lantheus' stock was trading at $50.96 on January 1st, 2023. Since then, LNTH shares have increased by 15.1% and is now trading at $58.64.
View the best growth stocks for 2023 here.

Lantheus saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 3,450,000 shares, a decrease of 5.5% from the December 31st total of 3,650,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is presently 3.1 days. Approximately 5.1% of the shares of the company are sold short.
View Lantheus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our LNTH earnings forecast.

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, November, 4th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. The medical equipment provider had revenue of $102.10 million for the quarter, compared to analysts' expectations of $97.13 million. Lantheus had a net margin of 13.35% and a trailing twelve-month return on equity of 37.77%. The business's quarterly revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.04 earnings per share.

Lantheus issued an update on its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of $0.95-$0.98 for the period, compared to the consensus EPS estimate of $0.86. The company issued revenue guidance of $243.00 million-$247.00 million, compared to the consensus revenue estimate of $238.01 million.

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Reinhart Partners Inc. (0.84%), Congress Asset Management Co. MA (0.50%), Allspring Global Investments Holdings LLC (0.45%), Assenagon Asset Management S.A. (0.45%), Peregrine Capital Management LLC (0.39%) and New York State Teachers Retirement System (0.33%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends.

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LNTH stock can currently be purchased for approximately $58.64.

Lantheus (NASDAQ:LNTH) has a market capitalization of $4.04 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71,280,000.00 in net income (profit) each year or $1.49 on an earnings per share basis.

The company employs 612 workers across the globe.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.